EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Comparing Genomic Profiles of ALK Fusion-Positive and ALK Fusion-Negative Nonsmall Cell Lung Cancer Patients

Wenchao Xia, Jing Yang, Hongbin Li, Ling Li, Jinfeng Liu

Global Medical Genetics · 01.06.2024 · 11 (02) · 175-186

DOI: 10.1055/s-0044-1787301 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Global Medical Genetics, erschienen am 01.06.2024. Verfasst von Wenchao Xia und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Tianjin Chest Hospital, Tianjin, People's Republic of China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anaplastic lymphoma kinase (ALK) fusion events account for 3 to 7% of genetic alterations in patients with nonsmall cell lung cancer (NSCLC). This study aimed to explore the landscape of ALK fusion-positive and ALK fusion-negative in a large cohort of NSCLC patients.

Methods

The formalin-fixed paraffin-embedded specimens of NSCLC patients who underwent next-generation sequencing from 2020 to 2023 in Yinfeng Gene Technology Co., Ltd. Clinical laboratory were included in this study.

Results

In the current study, a total of 180 (3.20%) patients tested positive for ALK fusions in 5,622 NSCLC samples. Within the ALK-positive cohort, a total of 228 ALK fusions were identified. Furthermore, five novel ALK fusion partners, including DAB1-ALK, KCMF1-ALK, KIF13A-ALK, LOC643770-ALK, and XDH-ALK were identified. In cases with ALK fusion-positive, TP53 alterations were the most prevalent (26.3%), followed by CDKN2A (8.4%), epidermal growth factor receptor (EGFR, 5.6%), and ALK (5.6%). By contrast, EGFR alterations were most prevalent (51%) in patients with ALK fusion-negative NSCLC, followed by TP53 (42.7%), KRAS (11.6%), and CDKN2A (11.3%). A total of 10 cases where ALK fusion co-occurred with EGFR mutations were also identified. Notably, the ALK fusion positivity rate was higher in younger patients (p < 0.0001) and in female patients (p = 0.0429). Additionally, positive ALK test results were more prevalent in patients with high programmed death-ligand 1 expression, especially when applying a 50% cutoff.

Conclusions

Collectively, these findings offer valuable genomic insights that could inform the personalized clinical care of patients with NSCLC harboring ALK fusions within the context of precision medicine.

Schlagwörter

Stichwörter der Autor:innen

ALK fusionNSCLCgenomic landscapenext-generation sequencing

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Tianjin Chest Hospital, Tianjin, People's Republic of China.
  • Department of Pathogenic Biology, Logistics University of Chinese People's Armed Police Force, Tianjin, People's Republic of China.
  • Department of Oncology, Rongcheng County People's Hospital, Baoding, People's Republic of China.
  • Department of Medicine, Yinfeng Gene Technology Co., Ltd., Jinan, People's Republic of China.
  • Department of Thoracic Surgery, The First Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China.

Zitieren

APA

Xia, W., Yang, J., Li, H., Li, L., & Liu, J. (2024). Comparing Genomic Profiles of ALK Fusion-Positive and ALK Fusion-Negative Nonsmall Cell Lung Cancer Patients. Global Medical Genetics, 11(02), 175-186. https://doi.org/10.1055/s-0044-1787301

Vancouver

Xia W, Yang J, Li H, Li L, Liu J. Comparing Genomic Profiles of ALK Fusion-Positive and ALK Fusion-Negative Nonsmall Cell Lung Cancer Patients. Global Medical Genetics. 2024;11(02):175-186. doi:10.1055/s-0044-1787301

BibTeX
@article{Xia2024,
  author = {Xia, Wenchao and Yang, Jing and Li, Hongbin and Li, Ling and Liu, Jinfeng},
  title = {Comparing Genomic Profiles of ALK Fusion-Positive and ALK Fusion-Negative Nonsmall Cell Lung Cancer Patients},
  journal = {Global Medical Genetics},
  year = {2024},
  volume = {11},
  number = {02},
  pages = {175--186},
  doi = {10.1055/s-0044-1787301}
}
Kostenlos starten →